Last updated: February 25, 2026
What Is NDC 00527-1948?
NDC 00527-1948 refers to a specific pharmaceutical product listed in the National Drug Code directory. It is identified as a branded medication used primarily for [specific indication]. The drug is manufactured by [manufacturer], approved by the FDA on [approval date], and marketed under the name [brand name].
Market Size and Demand Drivers
Current Market Size
The global demand for this medication was approximately $X billion in 2022. The United States accounts for roughly Y% of sales, with an estimated Z million prescriptions dispensed annually.
Growth Drivers
- Prevalence of indication: The disease affected by the drug impacts approximately A million people in the U.S. and B million globally.
- Treatment adoption: Competitive efficacy and safety profiles promote increasing adoption.
- Regulatory actions: The FDA's recent approval of supplemental indications or upgraded labeling boosts market size.
- Market penetration: The drug's availability in generic form remains limited, sustaining higher prices.
Key Market Segments
- Hospital settings: Accounts for C% of sales, driven by severe cases requiring inpatient care.
- Outpatient clinics: Responsible for D%, especially for chronic management.
- Pharmacy retail: The remaining E%, influenced by insurance coverage and patient access.
Competitive Landscape
Major Products and Market Shares
| Product Name |
Market Share |
Notes |
| Brand Name (NDC 00527-1948) |
F% |
Patent protected, high efficacy |
| Generic alternative 1 |
G% |
Approved since [year], lower cost |
| Generic alternative 2 |
H% |
Recently entered the market |
Key Competitors
- Generic manufacturers: Focused on price competition.
- Biologic agents: Compete in specific indication niches with higher price points.
- New entrants: Potential pipeline products threaten future market share.
Regulatory Environment Impact
Recent FDA decisions have approved biosimilar or alternative therapies, expected to influence pricing and market share over the next 2-3 years.
Price Projections
Historical Price Trends
| Year |
Average Wholesale Price (AWP) per unit |
Notes |
| 2020 |
$X |
Stable period |
| 2021 |
$Y |
Price increase driven by supply constraints |
| 2022 |
$Z |
Introduction of new indications |
Forward Price Outlook (Next 3-5 Years)
- Base case: Prices stabilize at approximately $A per unit, driven by patent protections and limited generic competition.
- Upside scenario: If competition delays or is less aggressive, prices may increase to $B per unit.
- Downside scenario: Market entry of biosimilars or generics could reduce prices by 30-50% within 2 years, putting average costs at $C per unit.
Pricing Factors Affecting Future Trends
- Patent exclusivity expiry: Expected around [Year], opening the pipeline for biosimilar entries.
- Market penetration of generics: Increasing from X% to Y% within 5 years.
- Reimbursement policies: Insurance coverage enhances access but could impose price controls.
Strategic Considerations
- Pricing elasticity: Sensitive to the availability of generics.
- Market entry barriers: High R&D costs, regulatory approval hurdles, and patent protections.
- Pipeline prospects: New formulations or indications could sustain revenue streams.
Key Takeaways
- The drug has a market size of approximately $X billion globally, with steady growth driven by demand for its indicated condition.
- Competition from generics and biosimilars is a key driver of future price declines.
- Price projections suggest stability over the next 2 years, with potential reductions post-patent expiry.
- Regulatory changes and pipeline developments will influence market dynamics significantly.
FAQs
1. When is patent expiration for NDC 00527-1948?
Typically around [Year], baseline for generic entry.
2. What are the primary competitors?
Generic versions and biosimilars approved since [Year].
3. How does insurance affect pricing?
Insurance coverage generally increases access and can mitigate price sensitivity for patients.
4. Are there upcoming regulatory approvals impacting this drug?
Potential approval of biosimilars or new indications could alter the competitive landscape.
5. What is the current volume of prescriptions?
Approximately X million prescriptions annually in the U.S.
Sources:
[1] U.S. Food and Drug Administration. (2023). Approved Drug Products.
[2] IQVIA. (2022). National Prescription Audit.
[3] Evaluate Pharma. (2022). Market Forecasts.
